首页> 外文期刊>Pediatric emergency care >Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises
【24h】

Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises

机译:酮胺输注急性小儿镰刀细胞疼痛危机中的疼痛控制

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives Sickle cell disease is the most common hemoglobin variant in the world and can present with recurrent vaso-occlusive painful crises. Pain control in these patients is often difficult and requires a multimodal approach. In patients with uncontrolled pain after traditional pain control methods, ketamine infusions have proven beneficial. Unfortunately, no source alone had described ketamine infusions for pediatric sickle cell patients. Our objective was to provide a thorough definitive reference for health care providers regarding the use of ketamine infusion for pain control in pediatric sickle cell painful crises. Methods Literature review. Results Low-dose ketamine infusions for pediatric patients with sickle cell disease painful crises resulted in improved pain scores and reduced opioid usage. Conclusions Ketamine infusions have shown promise in assisting physicians in appropriately treating pediatric sickle cell painful crises.
机译:目标镰状细胞疾病是世界上最常见的血红蛋白变异,并且可以出现经常发生的血管闭塞痛苦危机。 这些患者的疼痛控制往往难以困难,需要多式化的方法。 在传统疼痛控制方法后不受控制疼痛的患者中,氯胺酮输注已被证明有益。 不幸的是,单独源仅描述小儿镰刀细胞患者的氯胺酮输注。 我们的目标是为有关使用氯胺酮输注在小儿镰状细胞疼痛危机中使用氯胺酮输注来提供彻底的最明确的卫生保健提供者参考。 方法文献综述。 结果镰状细胞疾病痛苦危机的小儿科患者的低剂量氯胺酮输注导致疼痛评分改善和降低的阿片类药物使用。 结论氯胺酮输注表明了在适当治疗小儿镰刀细胞痛苦危机中辅助医生的承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号